KR20130018956A - 쓴맛이 감소된 나테글리니드 함유 제제 - Google Patents
쓴맛이 감소된 나테글리니드 함유 제제 Download PDFInfo
- Publication number
- KR20130018956A KR20130018956A KR1020127034106A KR20127034106A KR20130018956A KR 20130018956 A KR20130018956 A KR 20130018956A KR 1020127034106 A KR1020127034106 A KR 1020127034106A KR 20127034106 A KR20127034106 A KR 20127034106A KR 20130018956 A KR20130018956 A KR 20130018956A
- Authority
- KR
- South Korea
- Prior art keywords
- nateglinide
- weight
- oral solid
- water
- soluble polymer
- Prior art date
Links
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title claims abstract description 78
- 229960000698 nateglinide Drugs 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 235000019658 bitter taste Nutrition 0.000 title claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 68
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 238000009472 formulation Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000003826 tablet Substances 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 229920000609 methyl cellulose Polymers 0.000 claims description 13
- 239000001923 methylcellulose Substances 0.000 claims description 13
- 235000010981 methylcellulose Nutrition 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 210000000214 mouth Anatomy 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- -1 copolydon Polymers 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims description 5
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims description 2
- 235000001465 calcium Nutrition 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000011156 evaluation Methods 0.000 description 22
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- 235000019640 taste Nutrition 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005550 wet granulation Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 206010013911 Dysgeusia Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 101100120289 Drosophila melanogaster Flo1 gene Proteins 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229920003115 HPC-SL Polymers 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004233797 | 2004-08-10 | ||
JPJP-P-2004-233797 | 2004-08-10 | ||
PCT/JP2005/014647 WO2006016602A1 (ja) | 2004-08-10 | 2005-08-10 | 苦味の低減したナテグリニド含有製剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077003164A Division KR20070040389A (ko) | 2004-08-10 | 2005-08-10 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130018956A true KR20130018956A (ko) | 2013-02-25 |
Family
ID=35839371
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020127034106A KR20130018956A (ko) | 2004-08-10 | 2005-08-10 | 쓴맛이 감소된 나테글리니드 함유 제제 |
KR1020077003164A KR20070040389A (ko) | 2004-08-10 | 2005-08-10 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077003164A KR20070040389A (ko) | 2004-08-10 | 2005-08-10 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
Country Status (3)
Country | Link |
---|---|
JP (2) | JP5551852B2 (ja) |
KR (2) | KR20130018956A (ja) |
WO (1) | WO2006016602A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2658549A1 (en) * | 2006-08-08 | 2008-02-14 | Kissei Pharmaceutical Co., Ltd. | Oral disintegrating tablet having masked bitter taste and method for production thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS519712B2 (ja) * | 1972-12-29 | 1976-03-29 | ||
JPS58401B2 (ja) * | 1974-07-15 | 1983-01-06 | 明治製菓株式会社 | ケイコウヨウイヤクヒンソセイブツノ セイホウ |
JPH0717866A (ja) * | 1993-06-16 | 1995-01-20 | Meiji Seika Kaisha Ltd | 医薬組成物 |
EP1027036A2 (en) * | 1997-10-03 | 2000-08-16 | ELAN CORPORATION, Plc | Taste masked formulations |
JP2001019639A (ja) * | 1999-07-07 | 2001-01-23 | Nitto Yakuhin Kogyo Kk | 感冒固形製剤 |
CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
PL356300A1 (en) * | 1999-12-28 | 2004-06-28 | Ajinomoto Co, Inc. | Oral preparations for diabetes |
JP4284017B2 (ja) * | 2000-10-06 | 2009-06-24 | 武田薬品工業株式会社 | 固形製剤 |
CA2426263C (en) * | 2000-10-24 | 2010-05-25 | Ajinomoto Co., Inc. | Nateglinide-containing preparation |
EP1490035A1 (en) * | 2001-09-26 | 2004-12-29 | Pharmacia Corporation | Intraorally disintegrating valdecoxib compositions |
JP2004010611A (ja) * | 2002-06-06 | 2004-01-15 | Nisshin Yakuhin Kogyo Kk | マスキング組成物 |
-
2005
- 2005-08-10 KR KR1020127034106A patent/KR20130018956A/ko not_active Application Discontinuation
- 2005-08-10 KR KR1020077003164A patent/KR20070040389A/ko active IP Right Grant
- 2005-08-10 WO PCT/JP2005/014647 patent/WO2006016602A1/ja active Application Filing
- 2005-08-10 JP JP2006531680A patent/JP5551852B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-05 JP JP2012048419A patent/JP5578492B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2012121911A (ja) | 2012-06-28 |
JP5578492B2 (ja) | 2014-08-27 |
JPWO2006016602A1 (ja) | 2008-05-01 |
KR20070040389A (ko) | 2007-04-16 |
WO2006016602A1 (ja) | 2006-02-16 |
JP5551852B2 (ja) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2893940B1 (en) | Granulated material for tablet that rapidly disintegrates in mouth | |
JP5456795B2 (ja) | リナグリプチン及び必要に応じてsglt2阻害薬を含む医薬組成物、並びにその使用 | |
JP2021006534A (ja) | 新規製剤 | |
US7732492B2 (en) | Nateglinide-containing preparation | |
AU2006271314B2 (en) | Gastroretentive formulations and manufacturing process thereof | |
RU2527766C2 (ru) | Таблетки и гранулированные порошки, содержащие 6-фтор-3-гидрокси-2-пиразинкарбоксамид | |
WO2017114227A1 (zh) | 一种复方达格列净二甲双胍缓释片及其制备方法 | |
JPH10194969A (ja) | 錠剤組成物 | |
JP2002326927A (ja) | 塩酸メトホルミン含有速放性錠剤 | |
US20060240101A1 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
EP3856162A1 (en) | Pharmaceutical composition comprising vildagliptin and metformin and method of preparation thereof | |
WO2006123213A1 (en) | Modified release formulations of gliclazide | |
KR101421330B1 (ko) | 붕괴정 | |
CN103251594B (zh) | 瑞格列奈二甲双胍的片剂 | |
CN103251593B (zh) | 瑞格列奈二甲双胍组合物 | |
KR101383430B1 (ko) | 새로운 조합의 구강내 속붕해 필름형성 조성물 및 pde5 저해제가 함유된 구강내 속붕해 필름제제 | |
JPH1121236A (ja) | ロキソプロフェン・ナトリウム固形製剤 | |
KR20130018956A (ko) | 쓴맛이 감소된 나테글리니드 함유 제제 | |
KR100267525B1 (ko) | 시타라빈 옥포스페이트 경질 캡슐제 | |
JP6538321B2 (ja) | 経口組成物 | |
JP2005139086A (ja) | 速崩壊製剤 | |
JP2010001242A (ja) | レバミピド固形製剤及びその製造方法 | |
EP4045048A1 (en) | Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics | |
KR20210045404A (ko) | 다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제 | |
CN104434860A (zh) | 包合工艺制备的盐酸氨溴索渗透泵型药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |